# Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

> **NCT02403193** · PHASE1 · COMPLETED · sponsor: **Palobiofarma SL** · enrollment: 92 (actual)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** PBF-509_80 mg
- **DRUG:** PBF-509_160 mg
- **DRUG:** PBF-509_320 mg
- **DRUG:** PBF-509_640 mg
- **DRUG:** Combo PBF-509 (160 mg) + PDR001
- **DRUG:** Combo PBF-509 (320 mg) + PDR001
- **DRUG:** Combo PBF-509 (640 mg) + PDR001
- **DRUG:** RP2D (PBF-509+PDR001)_immuno naïve
- **DRUG:** Experimental: RP2D (PBF-509+PDR001)_immuno treated

## Key facts

- **NCT ID:** NCT02403193
- **Lead sponsor:** Palobiofarma SL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2021-10
- **Final completion:** 2021-11-24
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2022-01-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02403193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02403193, "Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02403193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*